

ASX Announcement

8 December 2025

Additional information on the US Department of Defence (DoD) & Veterans Affairs (VA) healthcare systems product supply agreement

ReNerve Limited (ASX, "ReNerve" or "the Company"), a leading Australian medical device innovator focused on solutions for peripheral nerve injury (PNI), today announced an update on its commercial operations, in particular its NervAlign® Nerve Cuff that has been approved for use across the US Department of Defence (DoD) and Veterans Affairs (VA) healthcare systems, representing a significant endorsement of ReNerve's NervAlign® nerve cuff technology. The following provides additional information pertaining to that product supply agreement following the company's announcement on 13 November 2025:

Name of the customer	US Department of Defence and Veterans Affairs (VA).
Term of contract	This is an ongoing product supply agreement for the ReNerve NervAlign Nerve Cuff. Through a tender process, ReNerve secured approval for purchase across DoD hospitals worldwide, as well as VA hospitals throughout the USA.
Nature of products to be supplied	ReNerve will supply the NervAlign Nerve Cuff on an ongoing basis and is now positioned to pursue sustained use and stocking opportunities across the global DoD network and the VA hospital system. This tender process approval establishes a long-term pathway for consistent product adoption and expanded clinical reach.
Significance of contract to ReNerve	While the initial order was not material in size relative to ReNerve's annual revenue, the impact is significant: this approval grants ReNerve preferred supplier status and opens access to hospitals across the DoD and VA healthcare systems. With this approval in place, ReNerve now has a standing, ongoing supply agreement that creates a strong foundation for future growth.
Any material conditions that need to be satisfied before the customer becomes legally bound to proceed	ReNerve's NervAlign Nerve Cuff is FDA market cleared and will be provided in accordance with its FDA guidelines.
Any other material information relevant to assessing impact of the contract that can impact share price	None



For personal use only

- ENDS -

This announcement has been approved for release by the Company's Board of Directors.

For further information and enquiries, please contact:

Dr Julian Chick
CEO & Managing Director
ReNerve Ltd
+61 (03) 9482 3940
info@renerve.com.au

Matthew Wright
Investor & Media Relations
NWR Communications
+61 (0) 451 896 420
matt@nwrcommunications.com.au

About ReNerve Limited (ASX:RNV)

ReNerve Limited (ASX:RNV) is transforming nerve repair and improving lives through breakthrough medical technology. Founded by a neurosurgeon and medtech researchers, ReNerve is a rapidly growing medical device company that has revolutionised peripheral nerve surgery with its innovative, ready-to-use solutions for peripheral nerve injuries (PNI). Our scientifically backed products are delivering measurably better outcomes for patients worldwide.

Proven Clinical Success

ReNerve's first flagship product, the FDA-cleared **NervAlign® Nerve Cuff**, is already making a dramatic difference in surgical outcomes across the United States. A recently announced clinical study has demonstrated remarkable results, showing that patients treated with the NervAlign® Nerve Cuff experienced post-surgical pain scores dropping from 7.1 to just 0.4, compared to from 7.1 to 3.3 without the device being used – a statistically significant improvement that's changing lives.

Comprehensive Product Portfolio

ReNerve is advancing a complete suite of nerve repair solutions:

- **NervAlign® Nerve Cuff** – Our bioabsorbable protective wrap, naturally absorbed within six months of surgery.
- **Deep Dermal tissue product** -- A unique deep dermal product used in the repair of reconstructive and cosmetic surgical cases.
- **Amniotic tissue product ranges** -- Three amniotic tissue product ranges used to aid the healing of wounds.
- **NervAlign® Nerve Conduit Range** – Next-generation nerve conduit leveraging advantages of eCOO technology in a material designed to facilitate nerve growth over short gaps between nerve ends.
- **NervAlign® Nerve Guide Matrix** – a customised and ready-to-use alternative to existing nerve grafts, for treatment of longer nerve gaps and more severe nerve injuries. It will eliminate the need for patients to undergo additional sural nerve harvesting.
- **NervAlign® Bionic Nerve** – Next-generation combination technology for the most challenging nerve repairs.

Market Leadership and Growth

With demonstrated market traction since the Company's 2022 product launch, ReNerve achieved 53% revenue growth in FY25, reaching \$271k in sales. Our high-margin, scalable products are positioning us as the go-to solution for surgeons seeking superior patient outcomes in the rapidly expanding global nerve repair market, valued at US\$1.6 billion in 2024 and is projected to reach \$6.2 billion by 2031.¹

Vision and Values

We're not just developing medical devices – we're engineering hope. By creating the ideal healing environment for nerve repair and regeneration, ReNerve bridges critical gaps in healthcare while empowering the human body's natural healing process. Our cleaner, safer, and more effective solutions represent the future of peripheral nerve surgery.

¹ Global Nerve Repair Biomaterials Market Research Report (2020 – 2031)